Table 1:
Clinicopathologic Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Treated With and Without Neoadjuvant Chemotherapy.
| Neoadjuvant therapy (N=97) | Immediate surgery (N=77) | All (N=174) |
P-value | |
|---|---|---|---|---|
| Age (median [range]) (y) | 68 [45–81] | 70 [37–90] | 68 [37–90] | 0.221 |
| Gender | ||||
| Male | 44 (45%) | 45 (58%) | 89 (52%) | 0.095 |
| Female | 53 (55%) | 32 (42%) | 85 (48%) | |
| Ethnicity | ||||
| Caucasian | 83 (86%) | 64 (83%) | 147 (84%) | 0.678 |
| Others | 14 (14%) | 13 (17%) | 27 (16%) | |
| Tumor size and location | ||||
| Size (median [range]) (mm)* | 22 [0–78] | 30 [5–75] | 27 [0–78] | <0.0001 |
| Head | 73 (75%) | 62 (81%) | 135 (78%) | 0.467 |
| Body or tail | 24 (25%) | 15 (19%) | 39 (22%) | |
| pT classification (AJCC 8th) | ||||
| pT0 | 1 (1%) | 0 (0%) | 1 (1%) | <0.0001 |
| pTis | 1 (1%) | 0 (0%) | 1 (1%) | |
| pT1 | 45 (46%) | 11 (14%) | 56 (32%) | |
| pT2 | 39 (40%) | 54 (70%) | 93 (53%) | |
| pT3 | 10 (10%) | 12 (16%) | 22 (13%) | |
| pT4 | 1 (1%) | 0 (0%) | 1 (1%) | |
| pN classification (AJCC 8th) | ||||
| pN0 | 53 (55%) | 12 (18%) | 65 (37%) | <0.0001 |
| pN1 | 30 (31%) | 38 (48%) | 68 (39%) | |
| pN2 | 14 (14%) | 27 (34%) | 41 (24%) | |
| pM classification (AJCC 8th) | ||||
| pM0 | 95 (98%) | 77 (100%) | 172 (99%) | 0.504 |
| pM1 | 2 (2%) | 0 (0%) | 2 (1%) | |
| pStage (AJCC 8th)** | ||||
| pStage 0 | 1 (1%) | 0 (0%) | 1 (1%) | <0.0001 |
| pStage I | 47 (48%) | 12 (16%) | 59 (34%) | |
| pStage II | 31 (32%) | 38 (49%) | 69 (40%) | |
| pStage III | 15 (15%) | 27 (35%) | 42 (24%) | |
| pStage IV | 2 (2%) | 0 (0%) | 2 (1%) | |
| Lymphovascular invasion | ||||
| Present | 36 (38%) | 43 (57%) | 79 (45%) | 0.0149 |
| Absent | 61 (62%) | 34 (43%) | 95 (55%) | |
| Perineural invasion | ||||
| Present | 66 (65%) | 72 (94%) | 138 (79%) | <0.0001 |
| Absent | 31 (35%) | 5 (6%) | 36 (21%) | |
| Histological grade | ||||
| G1 | NA | 5 (6%) | ||
| G2 | NA | 40 (52%) | ||
| G3 | NA | 30 (39%) | ||
| G4 | NA | 2 (3%) | ||
| Final pancreatic margin | ||||
| Positive | 8 (8%) | 12 (16%) | 20 (11%) | 0.155 |
| Negative | 89 (92%) | 65 (84%) | 154 (89%) | |
| Neoadjuvant therapy (NAC) | ||||
| NAC | 52 (54%) | NA | ||
| NAC+RT | 45 (46%) | NA | ||
| NAC regimen | ||||
| Gemcitabine based | 27 (28%) | NA | ||
| FOLFIRINOX based | 51 (53%) | NA | ||
| Combination | 16 (16%) | NA | ||
| Others | 3 (3%) | NA | ||
| Response to NAC (CAP score) | ||||
| Score 0 | 1 (1%) | NA | ||
| Score 1 | 25 (26%) | NA | ||
| Score 2 | 53 (55%) | NA | ||
| Score 3 | 18 (19%) | NA | ||
| Cancerization | ||||
| Present | 50 (52%) | 39 (51%) | 89 (51%) | 0.879 |
| Absent | 47 (48%) | 38 (49%) | 85 (49%) | |
*
Tumor size of invasive component
**
One pT0 case in NAC group was excluded according to the AJCC staging system.